Neurosense Therapeutics Ltd Financials
This page shows Neurosense Therapeutics Ltd (NRSN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Neurosense Therapeutics Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Neurosense Therapeutics Ltd earned -$0.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 18.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Neurosense Therapeutics Ltd held $166K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Neurosense Therapeutics Ltd invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 166.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NRSN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $5.7M-21.7% | $7.3M+30.2% | $5.6M+300.8% | $1.4M |
| SG&A Expenses | $4.9M+15.6% | $4.2M-12.0% | $4.8M-3.9% | $5.0M+212.2% | $1.6M |
| Operating Income | N/A | -$9.9M+17.8% | -$12.0M-14.2% | -$10.6M-253.6% | -$3.0M |
| Net Income | N/A | -$10.2M-1.0% | -$10.1M+3.7% | -$10.5M-225.8% | -$3.2M |
| EPS (Diluted) | -$0.44+18.5% | -$0.54+27.0% | -$0.74+18.7% | -$0.91 | -$0.52 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
NRSN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $1.0M-77.5% | $4.6M+43.6% | $3.2M-58.7% | $7.7M | N/A |
| Current Assets | $778K-82.3% | $4.4M+51.0% | $2.9M-60.5% | $7.4M | N/A |
| Cash & Equivalents | $166K-95.1% | $3.4M+28.0% | $2.6M-25.5% | $3.5M-68.0% | $11.1M |
| Total Liabilities | $2.6M+29.9% | $2.0M-59.7% | $4.9M+164.0% | $1.9M | N/A |
| Current Liabilities | $2.5M+26.3% | $2.0M-42.4% | $3.5M+100.4% | $1.7M | N/A |
| Total Equity | -$1.6M-160.4% | $2.6M+246.8% | -$1.8M-130.1% | $5.8M-46.1% | $10.8M |
| Retained Earnings | -$47.8M-30.3% | -$36.7M-40.3% | -$26.1M-63.1% | -$16.0M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NRSN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating Cash Flow | N/A | -$10.1M-21.3% | -$8.4M-9.7% | -$7.6M-394.9% | -$1.5M |
| Capital Expenditures | $8K+166.7% | $3K-89.7% | $29K-58.6% | $70K+311.8% | $17K |
| Free Cash Flow | N/A | -$10.1M-20.9% | -$8.4M-9.1% | -$7.7M-394.0% | -$1.6M |
| Investing Cash Flow | -$8K-900.0% | $1K-100.0% | $3.5M+196.6% | -$3.6M-21017.6% | -$17K |
| Financing Cash Flow | $4.4M-59.4% | $10.9M+174.5% | $4.0M+5.3% | $3.8M-68.3% | $11.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NRSN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Return on Equity | N/A | -395.3% | N/A | -179.5%-149.8pp | -29.7% |
| Return on Assets | N/A | -223.2%+94.2pp | -317.3%-181.4pp | -136.0% | N/A |
| Current Ratio | 0.31-1.9x | 2.21+1.4x | 0.84-3.4x | 4.28 | N/A |
| Debt-to-Equity | N/A | 0.77 | N/A | 0.32 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Neurosense Therapeutics Ltd Ranks
Frequently Asked Questions
What are Neurosense Therapeutics Ltd's total assets?
Neurosense Therapeutics Ltd (NRSN) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Neurosense Therapeutics Ltd's capital expenditures?
Neurosense Therapeutics Ltd (NRSN) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Neurosense Therapeutics Ltd's current ratio?
Neurosense Therapeutics Ltd (NRSN) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is Neurosense Therapeutics Ltd's debt-to-equity ratio negative or not reported?
Neurosense Therapeutics Ltd (NRSN) has negative shareholder equity of -$1.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.